Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SS)
CNY 87.32
(3.15%)
CNY 87.32
(3.15%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.28 Billion CNY | 86.13% |
| 2022 | 713.01 Million CNY | 24.22% |
| 2021 | 573.97 Million CNY | 69.33% |
| 2020 | 338.97 Million CNY | -13.86% |
| 2019 | 393.5 Million CNY | 263.89% |
| 2018 | 108.13 Million CNY | 110.83% |
| 2017 | 51.29 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 451.06 Million CNY | 8.18% |
| 2024 Q1 | 412.57 Million CNY | -4.97% |
| 2024 Q2 | 400.16 Million CNY | -3.01% |
| 2023 Q3 | 389.65 Million CNY | 31.39% |
| 2023 FY | 1.32 Billion CNY | 86.13% |
| 2023 Q4 | 434.13 Million CNY | 11.42% |
| 2023 Q2 | 296.56 Million CNY | 20.0% |
| 2023 Q1 | 247.14 Million CNY | 21.45% |
| 2022 Q3 | 207.15 Million CNY | 31.4% |
| 2022 Q2 | 157.65 Million CNY | 8.94% |
| 2022 Q1 | 144.71 Million CNY | -11.52% |
| 2022 FY | 713.01 Million CNY | 24.22% |
| 2022 Q4 | 203.48 Million CNY | -1.77% |
| 2021 Q2 | 138.82 Million CNY | 39.0% |
| 2021 Q4 | 163.54 Million CNY | -4.76% |
| 2021 FY | 573.97 Million CNY | 69.33% |
| 2021 Q1 | 99.87 Million CNY | -13.4% |
| 2021 Q3 | 171.72 Million CNY | 23.7% |
| 2020 Q3 | 77.07 Million CNY | 2902.36% |
| 2020 FY | 338.97 Million CNY | -13.86% |
| 2020 Q2 | -2.75 Million CNY | 97.91% |
| 2020 Q1 | -131.32 Million CNY | -193.15% |
| 2020 Q4 | 115.32 Million CNY | 49.62% |
| 2019 Q1 | -328.92 Million CNY | 0.0% |
| 2019 Q3 | 49.74 Million CNY | 222.04% |
| 2019 Q4 | 140.98 Million CNY | 183.41% |
| 2019 FY | 393.5 Million CNY | 263.89% |
| 2019 Q2 | -40.76 Million CNY | 87.61% |
| 2018 FY | 108.13 Million CNY | 110.83% |
| 2017 FY | 51.29 Million CNY | 0.0% |